DSGN - Design Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-164.5M

Cash

303.1M

Avg Qtr Burn

-15.05M

Short % of Float

30.89%

Insider Ownership

36.96%

Institutional Own.

70.11%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DT-216 Details Friedreich’s Ataxia	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.